Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CHRS

Coherus Biosciences Inc

Dec 13 • 04:00PM ET

1.61

Dollar change +0.11
Percentage change 7.33	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD ABBV VRTX REGN BIIB INCY BMRN NBIX EXEL

| Held by: IWM VTI IWN IBB VXF SCHA IWO IWC VTWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.10	Insider Own	4.02%	Shs Outstand	115.21M	Perf Week	-5.29%
Market Cap	199.09M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	0.00%	Shs Float	110.58M	Perf Month	106.75%
Income	-0.45M	PEG	-	EPS next Q	-0.31	Inst Own	66.08%	Short Float	27.78%	Perf Quarter	53.33%
Sales	304.34M	P/S	0.65	EPS this Y	113.96%	Inst Trans	-5.64%	Short Ratio	5.83	Perf Half Y	-4.73%
Book/sh	-0.76	P/B	-	EPS next Y	-222.35%	ROA	-0.08%	Short Interest	30.72M	Perf Year	-32.07%
Cash/sh	0.79	P/C	2.04	EPS next 5Y	-	ROE	-	52W Range	0.66 - 3.70	Perf YTD	-51.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.73%	ROI	-0.22%	52W High	-56.49%	Beta	0.85
Dividend TTM	-	Quick Ratio	1.09	Sales past 5Y	-2.24%	Gross Margin	42.97%	52W Low	143.83%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	1.25	EPS Y/Y TTM	99.70%	Oper. Margin	-43.04%	RSI (14)	63.60	Volatility	9.82% 15.43%
Employees	306	Debt/Eq	-	Sales Y/Y TTM	44.19%	Profit Margin	-0.15%	Recom	1.33	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	77.00%	Payout	-	Rel Volume	0.48	Prev Close	1.50
Sales Surprise	19.99%	EPS Surprise	44.92%	Sales Q/Q	-5.09%	Earnings	Nov 06 AMC	Avg Volume	5.27M	Price	1.61
SMA20	20.70%	SMA50	54.88%	SMA200	1.95%	Trades		Volume	2,544,064	Change	7.33%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-24	Downgrade	UBS	Buy → Neutral	$4 → $1.50
Nov-17-23	Initiated	Robert W. Baird	Outperform	$11
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy	$12
May-01-23	Initiated	Truist	Buy	$24
Mar-28-23	Upgrade	UBS	Neutral → Buy	$11
Jun-14-22	Initiated	UBS	Neutral	$7
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral	$15
Jul-16-20	Initiated	BofA Securities	Neutral	$20
Apr-17-20	Initiated	SunTrust	Buy	$26
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	Maxim Group	Buy	$25 → $27
Aug-02-19	Reiterated	H.C. Wainwright	Buy	$28 → $29
Jun-11-19	Initiated	Barclays	Overweight	$30
May-07-19	Initiated	H.C. Wainwright	Buy	$28
Aug-28-18	Initiated	H.C. Wainwright	Buy	$28
Mar-09-18	Reiterated	Maxim Group	Buy	$20 → $15
Aug-08-17	Reiterated	JP Morgan	Overweight	$32 → $25
Jun-13-17	Reiterated	Maxim Group	Buy	$44 → $40
May-05-17	Initiated	BMO Capital Markets	Outperform	$54

Show Previous Ratings

Dec-03-24 07:00AM	Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 million to Intas Pharmaceuticals Ltd. (GlobeNewswire) +24.82%
06:06AM	Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M (BioPharma Dive)
Nov-27-24 04:01PM	Coherus Management to Participate in the 2024 Citi Global Healthcare Conference (GlobeNewswire)
Nov-07-24 01:09PM	Q3 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) +13.29%
02:26AM	Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
05:15PM	Loading…
Nov-06-24 05:15PM	Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:08AM	Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +9.10%
Oct-30-24 04:20PM	Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-09-24 06:01PM	Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Sep-28-24 07:24AM	Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:28AM	Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges (Insider Monkey)
Aug-08-24 05:50PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.85%
04:45PM	Coherus BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 09:00AM	Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire) -7.14%
Jun-28-24 07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
Jun-27-24 08:26AM	Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction (GlobeNewswire)
Jun-05-24 09:00AM	Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors (GlobeNewswire)
May-30-24 09:00AM	Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 05:51PM	Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
09:00AM	Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA (GlobeNewswire)
May-13-24 09:23AM	Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating (MT Newswires) +10.00%
May-10-24 04:45PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript (Insider Monkey) -10.38%
May-09-24 05:15PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:30AM	Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan (GlobeNewswire)
May-08-24 09:00AM	Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer (GlobeNewswire)
04:30PM	Loading…
May-01-24 04:30PM	Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire) +5.10% +5.34%
Apr-24-24 10:02AM	Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.34%
Apr-08-24 08:30AM	Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting (GlobeNewswire)
Mar-16-24 03:35PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 06:28PM	Why Coherus Biosciences Stock Tumbled on Thursday (Motley Fool) -5.65%
07:15AM	Q4 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 05:32PM	Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ... (GuruFocus.com)
04:13PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update (GlobeNewswire)
Mar-05-24 04:01PM	Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 (GlobeNewswire)
Mar-04-24 01:00AM	Coherus Completes Divestiture of Ophthalmology Franchise (GlobeNewswire) -5.81%
Feb-23-24 05:33PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Feb-21-24 08:30AM	Coherus Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv (GlobeNewswire)
Feb-06-24 05:16PM	Why Coherus BioSciences Stock Jumped Today (Motley Fool) +14.85%
Feb-05-24 08:00AM	Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP (GlobeNewswire)
Jan-23-24 11:37AM	Why Coherus BioSciences Stock Is Sinking Today (Motley Fool) -6.98%
Jan-22-24 03:41PM	Why Coherus Biosciences Popped Today (Motley Fool) +5.74%
08:38AM	Why Is Coherus BioSciences (CHRS) Stock Up 17% Today? (InvestorPlace)
01:15AM	Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal (GlobeNewswire)
Jan-18-24 04:05PM	Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium (GlobeNewswire)
Jan-12-24 03:06AM	Here's Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS) (Insider Monkey)
Jan-04-24 08:00AM	INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI (toripalimab-tpzi) (PR Newswire)
Jan-03-24 09:00AM	Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 08:29AM	Coherus Announces U.S. Launch of LOQTORZI (GlobeNewswire) -5.71%
Dec-28-23 03:45PM	Why Coherus BioSciences Stock Jumped Today (Motley Fool) +20.45%
11:07AM	Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody (Zacks)
Dec-27-23 05:07PM	These Stocks Moved the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and More (Barrons.com) +23.39%
01:06PM	These Stocks Are Moving the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and More (Barrons.com)
Dec-26-23 04:01PM	Coherus Announces FDA Approval of UDENYCA ONBODY , a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv (GlobeNewswire) +7.92%
Dec-24-23 09:45AM	2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street (Motley Fool)
Dec-22-23 05:00PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire) +7.92%
Dec-11-23 08:30AM	Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx (GlobeNewswire)
Dec-07-23 05:55PM	Coherus BioSciences Announces CFO Transition Plans (GlobeNewswire)
Dec-06-23 04:00AM	Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-28-23 11:16AM	Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association (GlobeNewswire) +8.76%
Nov-10-23 03:15PM	Why Coherus BioSciences Was Plummeting This Week (Motley Fool)
Nov-07-23 03:37PM	Why Coherus Biosciences Stock Dropped Today (Motley Fool) -30.23%
10:46AM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:19AM	Q3 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:13PM	Coherus BioSciences Inc (CHRS) Reports 27% Rise in Q3 2023 Net Revenue (GuruFocus.com)
04:43PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:07PM	Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Nov-03-23 08:30AM	Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) +8.73%
Nov-02-23 08:00PM	Coherus BioSciences to Participate at Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-23 10:01AM	Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-30-23 06:00PM	Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire) +14.02% +11.30%
05:43PM	Why Coherus BioSciences Stock Soared Today (Motley Fool)
Oct-27-23 03:07PM	Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (GlobeNewswire)
Oct-24-23 07:41PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire) -11.16%
Oct-14-23 12:30PM	Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-11-23 10:42AM	Load Up, Says Citigroup, About These 2 Strong Buy Stocks (TipRanks)
Oct-09-23 09:49AM	Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody (Zacks)
Oct-05-23 04:45PM	Why Coherus BioSciences Stock Popped Today (Motley Fool) +9.46% +8.07%
08:30AM	Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA ONBODY (GlobeNewswire)
Oct-04-23 08:30AM	CIMERLI (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch (GlobeNewswire) -5.37%
Oct-02-23 09:00AM	Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day (GlobeNewswire)
Sep-27-23 09:10AM	Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Sep-26-23 10:53AM	Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down (Zacks)
Sep-25-23 08:30AM	FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections (GlobeNewswire) -9.19%
Sep-22-23 09:00PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire) +7.73%
Sep-08-23 09:05AM	Coherus Completes Surface Oncology Acquisition (GlobeNewswire)
08:31AM	Why Coherus BioSciences Stock Was Plunging This Week (Motley Fool)
Sep-01-23 06:51PM	Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire) -10.28%
04:01PM	Coherus BioSciences to Participate at Upcoming September Investor Conferences (GlobeNewswire)
Aug-31-23 04:01PM	Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote FOR the Proposed Merger with Coherus BioSciences (GlobeNewswire)
Aug-22-23 05:35PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Aug-03-23 07:43PM	Why Coherus BioSciences Stock Popped Today (Motley Fool) +17.74%
Aug-02-23 05:15PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:12PM	Coherus BioSciences: Q2 Earnings Snapshot (AP Finance)
04:01PM	Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wahlstrom Mats	Director	Feb 01 '24	Option Exercise	1.67	59,988	100,000	99,988	Feb 05 07:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CHRS

Coherus Biosciences Inc

Upgrade your FINVIZ experience